# Quoin Pharmaceuticals Ltd.: overview QNRX · Nasdaq · CIK 1671502 · [Healthcare](/sectors/healthcare.md) Pages: [Overview](/companies/qnrx.md) · [Financials](/companies/qnrx/financials.md) · [Filings](/companies/qnrx/filings.md) · [Insiders](/companies/qnrx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | [0.0](/filings/0001104659-22-045620.md) | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.01)](/filings/0001104659-22-045620.md) | not reported | not reported | not reported | not reported | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/qnrx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Dauntless Investment Group, LLC](/funds/2044285.md) | 2026-06-30 | $1.0m | 214,987 | | Added +18,395 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $1.0m | 211,538 | | Unchanged | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $965.5k | 199,486 | | Added +146,026 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $543.6k | 112,323 | | Added +36,076 | | [SummitTX Capital, L.P.](/funds/2052310.md) | 2026-06-30 | $485.5k | 100,300 | | Unchanged | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $370.0k | 76,446 | | Reduced −3,136 | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $363.0k | 75,000 | | Unchanged | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $352.0k | 72,730 | | Unchanged | | [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $338.8k | 70,000 | | Added +19,000 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $289.6k | 59,838 | | Unchanged | ## Recent filings [All 573 filings](/companies/qnrx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 06:35 ET | [8-K](/filings/0001104659-26-117080.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-117080 | | 2026-10-14 | 06:35 ET | [8-K](/filings/0001104659-26-115709.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-115709 | | 2026-10-02 | 16:42 ET | [DEF 14A](/filings/0001104659-26-113301.md) | Proxy statement, period 2026-11-12 | 0001104659-26-113301 | | 2026-09-22 | 16:15 ET | [8-K](/filings/0001104659-26-109639.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-109639 | | 2026-09-10 | 16:05 ET | [8-K](/filings/0001104659-26-106705.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-106705 | | 2026-08-28 | 10:31 ET | [8-K](/filings/0001104659-26-102917.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-102917 | | 2026-08-20 | 16:19 ET | [8-K](/filings/0001104659-26-099239.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 8.01 Other events | 0001104659-26-099239 | | 2026-08-14 | 16:06 ET | [8-K](/filings/0001104659-26-097094.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-097094 | | 2026-08-14 | 16:02 ET | [10-Q](/filings/0001104659-26-097064.md) | Quarterly report, period 2026-06-30 | 0001104659-26-097064 | | 2026-07-16 | 07:30 ET | [DEF 14A](/filings/0001104659-26-084078.md) | Proxy statement, period 2026-08-20 | 0001104659-26-084078 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-035251.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1671502 - Tickers: QNRX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: L3 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 20:22 ET. No prices; not investment advice.